Gastrointestinal Cancers: Progress with Targeted Therapies
/
RSS Feed
Robert Mayer
ROBERT MAYER, Dana-Farber Cancer Institute, Boston
One of the leading participants at the 2008 Gastrointestinal Cancers Symposium, Robert Mayer, gave Peter Goodwin his assessment of some of the emerging new therapies being announced, for colorectal, liver and pancreas cancers.
One of the leading participants at the 2008 Gastrointestinal Cancers Symposium, Robert Mayer, gave Peter Goodwin his assessment of some of the emerging new therapies being announced, for colorectal, liver and pancreas cancers.
LISTEN
[audio:https://www.audiomedica.com/podcasting/oncology/080126_robert_mayer.mp3]
You may also like...
Volume CT Lung Cancer Screening Cuts Cancer Deaths 24 Per Cent 7 Feb, 2020 - Adjuvant Checkpoint Inhibition Extends Disease-Free and Overall Survival in Patients with Stage III Melanoma 13 Oct, 2016
- Normal stem cells are not depleted in acute myeloid leukaemia and could be targeted therapeutically 9 Aug, 2013
Chronic myeloid leukaemia: third generation TKI, ponatinib, succeeds against the T 315 I mutation 18 Dec, 2012
